Salah Ali A Showiheen1, Antonia RuJia Sun1, Xiaoxin Wu1,2, Ross Crawford1,3, Yin Xiao1,4, R Mark Wellard1, Indira Prasadam5. 1. Institute of Health and Biomedical Innovation, Faculty of Science and Engineering, Queensland University of Technology, Kelvin Grove Campus, Brisbane, QLD, 4059, Australia. 2. Department of Orthopaedic Surgery, Second Xiangya Hospital, Central South University, Changsha, China. 3. Orthopedic Department, The Prince Charles Hospital, Brisbane, QLD, Australia. 4. Australia-China Centre for Tissue Engineering and Regenerative Medicine, Queensland University of Technology, Brisbane, QLD, Australia. 5. Institute of Health and Biomedical Innovation, Faculty of Science and Engineering, Queensland University of Technology, Kelvin Grove Campus, Brisbane, QLD, 4059, Australia. i.prasadam@qut.edu.au.
Abstract
PURPOSE OF THE REVIEW: Osteoarthritis (OA) is a multifactorial and progressive disease affecting whole synovial joint. The extract pathogenic mechanisms and diagnostic biomarkers of OA remain unclear. In this article, we review the studies related to metabolomics of OA, discuss the biomarkers as a tool for early OA diagnosis. Furthermore, we examine the major studies on the application of metabolomics methodology in the complex context of OA and create a bridge from findings in basic science to their clinical utility. RECENT FINDINGS: Recently, the tissue metabolomics signature permits a view into transitional phases between the healthy and OA joint. Both nuclear magnetic resonance spectroscopy (NMR) and mass spectrometry-based metabolomics approaches have been used to interrogate the metabolic alterations that may indicate the complex progression of OA. Specifically, studies on alterations pertaining to lipids, glucose, and amino acid metabolism have aided in the understanding of the complex pathogenesis of OA. The discovery of identified metabolites could be important for diagnosis and staging of OA, as well as for the assessment of efficacy of new drugs.
PURPOSE OF THE REVIEW: Osteoarthritis (OA) is a multifactorial and progressive disease affecting whole synovial joint. The extract pathogenic mechanisms and diagnostic biomarkers of OA remain unclear. In this article, we review the studies related to metabolomics of OA, discuss the biomarkers as a tool for early OA diagnosis. Furthermore, we examine the major studies on the application of metabolomics methodology in the complex context of OA and create a bridge from findings in basic science to their clinical utility. RECENT FINDINGS: Recently, the tissue metabolomics signature permits a view into transitional phases between the healthy and OA joint. Both nuclear magnetic resonance spectroscopy (NMR) and mass spectrometry-based metabolomics approaches have been used to interrogate the metabolic alterations that may indicate the complex progression of OA. Specifically, studies on alterations pertaining to lipids, glucose, and amino acid metabolism have aided in the understanding of the complex pathogenesis of OA. The discovery of identified metabolites could be important for diagnosis and staging of OA, as well as for the assessment of efficacy of new drugs.
Authors: Salah Abdelrazig; Catharine A Ortori; Michael Doherty; Ana M Valdes; Victoria Chapman; David A Barrett Journal: Metabolomics Date: 2021-03-03 Impact factor: 4.290
Authors: Clara Pertusa; Damián Mifsut; José Manuel Morales; Juan J Tarín; Antonio Cano; Daniel Monleón; Miguel Ángel García-Pérez Journal: Metabolites Date: 2022-07-24
Authors: Chwan-Li Shen; Bruce A Watkins; Chanaka Kahathuduwa; Ming-Chien Chyu; Masoud Zabet-Moghaddam; Moamen M Elmassry; Hui-Ying Luk; Jean-Michel Brismée; Ami Knox; Jaehoon Lee; Mimi Zumwalt; Rui Wang; Tor D Wager; Volker Neugebauer Journal: Front Med (Lausanne) Date: 2022-01-03